The FDA granted accelerated approval of a new Alzheimer’s disease medication called Leqembi, made by the pharmaceutical company Eisai Global based on its ability to “may” slow down the progression of cognitive decline early on in the disease. It works by decreasing the number of amyloid plaques in the brain which appear to be the key...Read More
